The estimated Net Worth of International S.C.A.Invus P... is at least $3.91 Million dollars as of 29 May 2018. International P owns over 450,000 units of Scholar Rock Corp stock worth over $3,910,500 and over the last 6 years International sold SRRK stock worth over $0.
International has made over 1 trades of the Scholar Rock Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently International bought 450,000 units of SRRK stock worth $6,300,000 on 29 May 2018.
The largest trade International's ever made was buying 450,000 units of Scholar Rock Corp stock on 29 May 2018 worth over $6,300,000. On average, International trades about 450,000 units every 0 days since 2018. As of 29 May 2018 International still owns at least 450,000 units of Scholar Rock Corp stock.
You can see the complete history of International P stock trades at the bottom of the page.
International's mailing address filed with the SEC is Place Sainte-Gudule 19, 1000 Bruxelles, Belgium.
Over the last 6 years, insiders at Scholar Rock Corp have traded over $8,613,447 worth of Scholar Rock Corp stock and bought 8,895,194 units worth $64,726,758 . The most active insiders traders include Timothy A Springer, Srinivas Akkaraju, and Amir Nashat. On average, Scholar Rock Corp executives and independent directors trade stock every 55 days with the average trade being worth of $1,953,616. The most recent stock trade was executed by Caryn Parlavecchio on 16 August 2024, trading 1,451 units of SRRK stock currently worth $13,538.
scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s
Scholar Rock Corp executives and other stock owners filed with the SEC include: